The goals of this retrospective study were to determine the patient characteristics of dogs with high-grade primary mediastinal lymphoma and to determine outcome and associated prognostic factors. A total of 42 dogs were identified, in which 36 received treatment and had follow-up information available. The most common clinical signs included lethargy, anorexia and polyuria/ polydipsia. Hypercalcemia and pleural effusion were common findings at diagnosis. The phenotype was almost exclusively T-cell, most often in association with lymphoblastic cytomorphology as defined by the World Health Organization (WHO) lymphoma classification scheme. The overall progression-free survival (PFS) and overall survival (OS) were 133 and 183 days, respectively.
| INTRODUCTION
Lymphoma is one of the most common neoplasms diagnosed in dogs and is estimated to account for 7% to 24% of all canine tumours and 83% of all canine hematopoietic malignancies. 1 The majority of dogs diagnosed with lymphoma present with multicentric disease, and mediastinal involvement in the multicentric disease setting has been associated with the T-cell phenotype. Mediastinal involvement is reported to occur in 22% to 35.9% of dogs with lymphoma, and for dogs with the T-cell phenotype, mediastinal involvement is reported to be up to 54%. [2] [3] [4] [5] Both hypercalcemia and the presence of a mediastinal mass are associated with non-indolent T-cell phenotype, and the presence of either has been associated with a worse outcome as compared with high-grade B-cell lymphoma. [6] [7] [8] Anatomic localization to the mediastinum accounts for approximately 5% of cases, though this patient population has not been well described in the literature. Primary mediastinal lymphoma has not been well described in the veterinary literature. In people, mediastinal lymphoma can be either of T-cell or B-cell phenotype (T-lymphoblastic lymphoma or mediastinal large B-cell lymphoma, respectively), and reported treatment options include multi-agent chemotherapy protocols, immunotherapy and mediastinal irradiation. 15, 16 To the authors' knowledge, there are no published data regarding patient and tumour 
| Statistical analysis
Continuous data were tested for normality using the D'Agostino- Kaplan-Meier estimation was used to calculate PFS and OS; log-rank (Mantel-Cox) analysis was used to assess associations between patient and treatment factors and outcome. Cases were censored if they were still alive at last follow-up. All deaths were considered to be attributable to disease. A P-value of <.05 was considered statistically significant. All statistical analyses were performed using commercially available software (Prism v. 6.0d, GraphPad Software, La Jolla, California).
3 | RESULTS
| Patient population
Ninety-five patient records were screened for potential enrolment based on a medical record search for mediastinal lymphoma as the clinical diagnosis. Fifty-three cases were excluded due to the presence of peripheral lymphadenopathy. Forty-two dogs met the inclusion criteria for the study.
The mean age and weight of dogs were 7.8 years (range 2.5- Neoplastic lymphocyte lineage was determined at diagnosis by immunophenotyping in 17 cases and molecular clonality PCR in 1 case. All 18 were confirmed to be T-cell lymphoma via immunocytochemistry (ICC) (n = 11), immunohistochemistry (n = 5), flow cytometry (n = 1) and molecular clonality PCR (n = 1). In 2 instances, more than one method was used (ICC or flow cytometry + molecular clonality PCR) and results were concordant in both. Of these 18 confirmed T-cell lymphomas, 16 had samples available for morphologic assessment, and 10 were classified as lymphoblastic lymphoma and 6 as large-cell lymphoma. An additional 16 cases had stained cytologic smears available for DNA extraction and subsequent molecular clonality PCR. Of these 10 were confirmed as T-cell lymphoma, 1 as B-cell lymphoma, 1 ambiguous result (clonal at both B-and T-cell loci) and 4 yielded DNA that was not amplifiable. Of the 10 lymphomas confirmed as T-cell by molecular clonality PCR, 6 were lymphoblastic and 4 were large-cell lymphomas. The single B-cell lymphoma had large-cell morphology. In total, 29 cases had definitive lineage assignment with 28 being T-cell lymphoma and 1 being B-cell lymphoma.
Results of initial blood work and staging diagnostic tests were available for 42 cases and the most common abnormalities are included in Table 1 
| Treatment and patient outcome
Three dogs were euthanized at diagnosis and 3 additional dogs were lost to follow-up immediately after diagnosis. Chemotherapy protocols for the remaining 36 dogs included prednisone alone (n = 3), Lasparaginase with prednisone (n = 3), single agent doxorubicin with prednisone (n = 1), MOPP (n = 1), alternating chlorambucil and cyclophosphamide with prednisone (n = 1) and CHOP (n = 27). Four dogs received radiation therapy (RT) in additional to CHOP-based chemotherapy; 2 were treated in conjunction with their initial treatment and 2 were treated in the relapse setting (protocols described below).
Re-evaluation of thoracic radiographs to assess response to treatment was not consistently performed in this patient population.
Of the dogs treated with a CHOP protocol (n = 27), 26 Previous publications have reported that dogs with mediastinal masses in the multicentric lymphoma disease setting have a worse prognosis than dogs without mediastinal involvement; however, these studies did not evaluate phenotype. 6, 22 When subsets of patients with a T-cell phenotype have been evaluated, mediastinal involvement has not been reported to be a negative prognostic factor. 4, 5, 14 Only a single dog in this study was determined to have a Bcell phenotype, and the outcome data is consistent with previously published reports on high-grade T-cell lymphoma, indicating that primary mediastinal lymphoma typically represents a variant of highgrade T-cell lymphoma.
Hypercalcemia was not found to be prognostic for PFS or OS in this study. Previous studies have reported hypercalcemia to be prognostic for survival; however, more recent studies evaluating only high-grade T-cell lymphoma have not established the presence of hypercalcemia as a negative predictor of outcome for this disease. [4] [5] [6] 14, 23 This study provides further evidence that hypercalcemia is not likely an independent negative prognostic factor for lymphoma outcome but rather a marker of high-grade T-cell phenotype.
The only patient variable identified in this study to be prognostic radiation. It is possible that this may not be an independent effect on outcome as a multivariate analysis was not performed, and therefore could be impacted by other confounding variables that were not elucidated in this study.
Another goal of this study was to characterize the lineage and cell morphology of primary mediastinal lymphoma in dogs and determine any associations with hypercalcemia, pleural effusion or a worse outcome. All but one lymphoma in this study was of T-cell origin.
While dogs with a lymphoblastic subtype were significantly more likely to be hypercalcemic, there was no difference noted in outcome between dogs with lymphoblastic lymphoma compared with the other subtypes observed. The predominance of the WHO lymphoblastic morphologic type in this study is similar to a previous study evaluating lymphoma in the boxer breed. Interestingly, in that study, 6 dogs were also described as having mediastinal T-cell lymphoblastic lymphoma. 24 In people, the most common mediastinal non-Hodgkin lymphomas are primary mediastinal large B-cell lymphoma and lymphoblastic T-cell lymphoma. 18, 19 The variant of lymphoma described in the dogs in this publication is likely similar to T-cell lymphoblastic lymphoma/ leukaemia in humans, which is characterized by the presence of a mediastinal mass in up to 91% of patients. RT have yet to be elucidated with either cranial irradiation or targeted (local) radiotherapy being utilized in several reports. 25 Some studies have shown survival benefit in subsets of patients with T-cell lymphoblastic lymphoma while others have not. 16, 28, 29 With the advent of monoclonal antibody therapy, some studies have suggested that in patients with diffuse large B-cell mediastinal lymphoma, rituximab may reduce the benefit of RT in patients that achieve a metabolic complete remission with chemotherapy alone, while others have suggested it may still play a role. [30] [31] [32] The dogs treated with RT in this study were few in number and treated with varying protocols, but it is interesting to note that 2 of There are inherent limitations in this study due to its retrospective design, including incomplete staging, inconsistent patient follow-up and variable treatment protocols. To better assess the effect of treatment protocol on outcome, the treatment groups were categorized as CHOP-based vs other. The numbers in treatment groups other than CHOP were small, therefore it was impossible to accurately compare the efficacy of CHOP to other chemotherapy protocols, such as MOPP. A prospective trial with larger numbers would be required to better determine the most efficacious chemotherapy protocols.
Staging diagnostics were not standardized and were incomplete for some dogs, potentially underestimating the stage of disease for some dogs in this study. Not all dogs had an abdominal ultrasound performed, and there were patients with possible intra-abdominal disease that did not have aspirates performed to confirm organ involvement. This led to the inclusion of dogs that had either confirmed (n = 1) or possible (n = 5) intra-abdominal disease. These dogs were included in this study as they lacked peripheral lymphadenopathy, their presenting clinical signs were attributable to the presence of a large mediastinal mass, and questionable prognostic value of hepatic and splenic aspirates in lymphoma staging. 33 PFS is generally the preferred endpoint for evaluating a population of dogs undergoing treatment for a certain disease given that OS is influenced by owner elected euthanasia prior to death from disease. While PFS was reported in this study, it is important to note the accuracy is inherently flawed given this is a disease characterized by internal lesions without peripheral lymphadenopathy. Thus, relapse could have occurred sooner than what was reported.
Response and relapse were also difficult to document retrospectively given lack of standardization with restaging diagnostics and many dogs were censored from PFS analysis for this reason. Primary care veterinarians evaluated many of the dogs at relapse and for euthanasia, so relapse may be under-reported in this study, and the location reported may not be representative of all dogs with primary mediastinal lymphoma.
In summary, primary mediastinal lymphoma in dogs is characterized by nonspecific clinical signs, a T-cell phenotype most often with WHO lymphoblastic morphology, frequent hypercalcemia and pleural effusion. Prognosis for this disease is poor, but survival is improved when patients are treated with a multi-agent chemotherapy protocol.
